The renin–aldosterone system and drospirenone

  title={The renin–aldosterone system and drospirenone},
  author={Wolfgang Oelkers},
  journal={Gynecological Endocrinology},
  pages={83 - 87}
  • W. Oelkers
  • Published 1 January 2002
  • Medicine
  • Gynecological Endocrinology
8 Citations

Repurposing existing drugs for COVID-19: an endocrinology perspective

While dexamethasone may reduce mortality in severely ill patients with COVID-19, in the absence of evidence of any specific drug for mild-to-moderate COVID, researchers should consider testing existing drugs due to their favorable safety, familiarity, and cost profile.

Scientific Evidences Supporting the Activation of the Renin-Angiotensin-Aldosterone System during Estral Cycle and Pregnancy in Mares

  • K. SatuéA. Muñoz
  • Biology, Medicine
    Selected Chapters from the Renin-Angiotensin System
  • 2020
In mares, the research team has been investigating the changes of RAAS in mares during the estral cycle and during pregnancy, and these results are presented in the current chapter, comparing with the data previously reported for women and laboratory animals.

Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review

A systematic literature review on the impact of MHT containing MP on body weight, body mass index (BMI), and glucose metabolism, the following conclusions can be drawn: estrogens combined with MP either do not change or reduce body weight in normal weight postmenopausal women.

Kombinierte Hormonersatztherapie mit 1 mg Östradiol und 2 mg Drospirenon

A new combined formulation for hormone replacement therapy in climacteric women containing 1 mg estradiol and 2 mg drospirenone contains partial antiandrogenic and antimineralocorticoid effects and weight gain and blood pressure are influenced positively.

Bibliography Current World Literature

  • R. Caddell
  • Computer Science
    Coronary artery disease
  • 2000
The bibliography has been grouped into topics that relate to the reviews in this issue, and the number in square brackets following a selected paper, for example [7], refers to its number in the annotated references of the corresponding review.



Effect of estrogens and gestagens on exchangeable sodium.

The hypertension that occurs from the administration of the oral contraceptive may be a result of a mild hyperaldosterone state from the stimulation of the renin-angiotensin system combined with a mild direct mineralocorticoid effect from the synthetic gestation coupled with the suppression of natural progesterone with its "antimineralocorted" effect.

Oral contraceptives and high blood pressure.

It is suggested oral contraceptives not be given to patients with previous toxemia renal disease or family history of hypertension, as evidence implicates the renin-aldosterone system as causing increased blood pressure.

Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women.

It is concluded that DHSP may be a suitable partner of ethinyl estradiol as a constituent of an oral contraceptive, since its progestogenic and antialdosterone profile is similar to that of progesterone.

Effects of ethinylestradiol on the renin-angiotensin-aldosterone-system and on plasma transcortin in women and men.

The results indicate that no safe conclusions on metabolic effects of estrogen treatment in women can be drawn from experiments carried out in male subjects, and it is likely that sex differences in the response of plasma renin substrate to the estrogen are due to differences in hepatic synthesis and/or release of renIn substrate.

Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man.

The influence of treatment with progesterone and with 4 synthetic progestagens for 6 days on sodium balance and on different factors of the renin-aldosterone system was investigated in 20 young healthy men on a fixed sodium intake.

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.

To the authors' knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure and may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.